Base de dados : MEDLINE
Pesquisa : D03.383.663.283.446.520.079 [Categoria DeCS]
Referências encontradas : 1119 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 112 ir para página                         

  1 / 1119 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219912
[Au] Autor:Góis M; Azevedo A; Carvalho F; Nolasco F
[Ad] Endereço:Centro Hospitalar de Lisboa Central, Lisboa, Portugal.
[Ti] Título:Anticoagulant-related nephropathy in a patient with IgA nephropathy.
[So] Source:BMJ Case Rep;2017, 2017 Feb 20.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Anticoagulant-related nephropathy is a type of acute kidney injury caused by overcoagulation. We describe a case of an 84-year-old man with arterial hypertension, coronary heart disease and atrial fibrillation treated with acenocoumarol, who presented with haematoproteinuria and acute kidney injury during a phase of excessive anticoagulation. In addition to IgA nephropathy, renal biopsy also revealed acute tubular necrosis, red blood cell casts and positive iron staining in tubular cells. After this acute episode, renal function improved and proteinuria decreased below the nephrotic range.
[Mh] Termos MeSH primário: Acenocumarol/efeitos adversos
Lesão Renal Aguda/induzido quimicamente
Anticoagulantes/efeitos adversos
Glomerulonefrite por IGA/complicações
[Mh] Termos MeSH secundário: Lesão Renal Aguda/complicações
Lesão Renal Aguda/patologia
Idoso de 80 Anos ou mais
Glomerulonefrite por IGA/patologia
Seres Humanos
Necrose Tubular Aguda/complicações
Necrose Tubular Aguda/patologia
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170310
[Lr] Data última revisão:
170310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE


  2 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27967328
[Au] Autor:Ragia G; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
[Ad] Endereço:DNALEX S.A., Leontaridou 2, Alexandroupolis, Greece.
[Ti] Título:A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.
[So] Source:Pharmacogenomics;18(1):23-34, 2017 Jan.
[Is] ISSN:1744-8042
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: To generate and validate a pharmacogenomic-guided (PG) dosing algorithm for acenocoumarol in the Greek population. To compare its performance with other PG algorithms developed for the Greek population. PATIENTS & METHODS: A total of 140 Greek patients participants of the EU-PACT trial for acenocoumarol, a randomized clinical trial that prospectively compared the effect of a PG dosing algorithm with a clinical dosing algorithm on the percentage of time within INR therapeutic range, who reached acenocoumarol stable dose were included in the study. RESULTS: CYP2C9 and VKORC1 genotypes, age and weight affected acenocoumarol dose and predicted 53.9% of its variability. EU-PACT PG algorithm overestimated acenocoumarol dose across all different CYP2C9/VKORC1 functional phenotype bins (predicted dose vs stable dose in normal responders 2.31 vs 2.00 mg/day, p = 0.028, in sensitive responders 1.72 vs 1.50 mg/day, p = 0.003, in highly sensitive responders 1.39 vs 1.00 mg/day, p = 0.029). The PG algorithm previously developed for the Greek population overestimated the dose in normal responders (2.51 vs 2.00 mg/day, p < 0.001). CONCLUSION: Ethnic-specific dosing algorithm is suggested for better prediction of acenocoumarol dosage requirements in patients of Greek origin.
[Mh] Termos MeSH primário: Acenocumarol/administração & dosagem
Algoritmos
Anticoagulantes/administração & dosagem
Farmacogenética/métodos
Vigilância da População
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Relação Dose-Resposta a Droga
União Europeia
Feminino
Seguimentos
Grécia/etnologia
Seres Humanos
Masculino
Vigilância da População/métodos
Estudos Prospectivos
Método Simples-Cego
Vitamina K/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anticoagulants); 12001-79-5 (Vitamin K); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170803
[Lr] Data última revisão:
170803
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161215
[St] Status:MEDLINE
[do] DOI:10.2217/pgs-2016-0126


  3 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27883912
[Au] Autor:Baranowska I; Buszewski B; Namiesnik J; Konieczka P; Magiera S; Polkowska-Motrenko H; Koscielniak P; Gadzala-Kopciuch R; Wozniakiewicz A; Samczynski Z; Kochanska K; Rutkowska M
[Ad] Endereço:Department of Inorganic, Analytical Chemistry and Electrochemistry, Faculty of Chemistry, Silesian University of Technology, 7 M. Strzody Str., 44-100 Gliwice, Poland. Electronic address: irena.baranowska@polsl.pl.
[Ti] Título:Development of potential candidate reference materials for drugs in bottom sediment, cod and herring tissues.
[So] Source:Chemosphere;169:181-187, 2017 Feb.
[Is] ISSN:1879-1298
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Regular use of a reference material and participation in a proficiency testing program can improve the reliability of analytical data. This paper presents the preparation of candidate reference materials for the drugs metoprolol, propranolol, carbamazepine, naproxen, and acenocoumarol in freshwater bottom sediment and cod and herring tissues. These reference materials are not available commercially. Drugs (between 7 ng/g and 32 ng/g) were added to the samples, and the spiked samples were freeze-dried, pulverized, sieved, homogenized, bottled, and sterilized by γ-irradiation to prepare the candidate materials. Procedures for extraction and liquid chromatography coupled with tandem mass spectrometry were developed to determine the drugs of interest in the studied material. Each target drug was quantified using two analytical procedures, and the results obtained from these two procedures were in good agreement with each other. Stability and homogeneity assessments were performed, and the relative uncertainties due to instability (for an expiration date of 12 months) and inhomogeneity were 10-25% and 4.0-6.8%, respectively. These procedures will be useful in the future production of reference materials.
[Mh] Termos MeSH primário: Monitoramento Ambiental/métodos
Peixes/metabolismo
Poluentes Químicos da Água/análise
[Mh] Termos MeSH secundário: Acenocumarol/análise
Acenocumarol/metabolismo
Animais
Carbamazepina/análise
Carbamazepina/metabolismo
Cromatografia Líquida/métodos
Monitoramento Ambiental/normas
Metoprolol/análise
Metoprolol/metabolismo
Naproxeno/análise
Naproxeno/metabolismo
Propranolol/análise
Propranolol/metabolismo
Padrões de Referência
Reprodutibilidade dos Testes
Alimentos Marinhos
Espectrometria de Massas em Tandem/métodos
Poluentes Químicos da Água/metabolismo
Poluentes Químicos da Água/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Water Pollutants, Chemical); 33CM23913M (Carbamazepine); 57Y76R9ATQ (Naproxen); 9Y8NXQ24VQ (Propranolol); GEB06NHM23 (Metoprolol); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170119
[Lr] Data última revisão:
170119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161125
[St] Status:MEDLINE


  4 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27863991
[Au] Autor:García-Fernández A; Roldán V; Rivera-Caravaca JM; Lip GYH; Marín F
[Ad] Endereço:Cardiology Service, Alicante University General Hospital, ISABIAL - FISABIO Foundation, Alicante, Spain. Electronic address: ama_garcia@hotmail.com.
[Ti] Título:Applicability of the modified CHA DS -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients.
[So] Source:Eur J Intern Med;38:e21-e22, 2017 Mar.
[Is] ISSN:1879-0828
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticoagulantes/administração & dosagem
Fibrilação Atrial/complicações
Fibrilação Atrial/terapia
Acidente Vascular Cerebral/diagnóstico
Tromboembolia/epidemiologia
[Mh] Termos MeSH secundário: Acenocumarol/administração & dosagem
Idoso
Idoso de 80 Anos ou mais
Cardioversão Elétrica
Feminino
Seres Humanos
Masculino
Meia-Idade
Modelos de Riscos Proporcionais
Curva ROC
Medição de Risco/métodos
Fatores de Risco
Índice de Gravidade de Doença
Espanha
Tromboembolia/etiologia
[Pt] Tipo de publicação:LETTER; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Anticoagulants); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161120
[St] Status:MEDLINE


  5 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27756577
[Au] Autor:Lanas F; Castro C; Vallejos C; Bustos L; de La Puente C; Velasquez M; Zaror C
[Ad] Endereço:Centro de Excelencia CIGES, Universidad La Frontera, Montt 112, Temuco, Chile; Universitat Autònoma de Barcelona, Spain. Electronic address: lanastomas@gmail.com.
[Ti] Título:Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile.
[So] Source:J Clin Epidemiol;86:75-83, 2017 Jun.
[Is] ISSN:1878-5921
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Nonvalvular atrial fibrillation (NVAF) is a risk factor for ischemic stroke and systemic embolism. New oral anticoagulants are currently available. The objective of this study was to assess the incremental cost-utility ratio (ICUR) for apixaban vs. acenocoumarol in patients treated in Chile's public health system. STUDY DESIGN AND SETTING: We assessed cost-utility from the payer perspective with a lifetime Markov model. Epidemiologic characteristics, costs, and utilities were obtained from a Chilean cohort; data were completed with information from international literature. RESULTS: Incremental costs when using apixaban vs. acenocoumarol over a lifetime are CH$2,108,600 with an incremental effectiveness of 0.173 years of life gained (YLG) and 0.182 quality-adjusted life-year (QALY). The ICUR of apixaban vs. acenocoumarol was CH$12,188,439 per YLG and CH$11,585,714 per QALY. One to 3 times gross domestic product (GDP) per capita threshold is acceptable based on World Health Organization (WHO) norms. Chilean GDP per capita was CH$7,797,021 in 2013. The sensitivity analysis shows that these results are sensitive to the ischemic stroke risk with apixaban, and the intracranial hemorrhage risk due to the use of acenocoumarol. CONCLUSION: The use of apixaban in patients with NVAF in moderate-to-high risk of stroke is cost-effective, considering the payment threshold suggested by WHO.
[Mh] Termos MeSH primário: Acenocumarol/economia
Acenocumarol/uso terapêutico
Fibrilação Atrial/complicações
Pirazóis/economia
Pirazóis/uso terapêutico
Piridonas/economia
Piridonas/uso terapêutico
Acidente Vascular Cerebral/prevenção & controle
[Mh] Termos MeSH secundário: Idoso
Anticoagulantes/economia
Anticoagulantes/uso terapêutico
Chile
Análise Custo-Benefício/economia
Análise Custo-Benefício/estatística & dados numéricos
Estudos Epidemiológicos
Inibidores do Fator Xa/economia
Inibidores do Fator Xa/uso terapêutico
Feminino
Seres Humanos
América Latina
Masculino
Risco
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Factor Xa Inhibitors); 0 (Pyrazoles); 0 (Pyridones); 3Z9Y7UWC1J (apixaban); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161021
[St] Status:MEDLINE


  6 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27935941
[Au] Autor:van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
[Ad] Endereço:Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
[Ti] Título:Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
[So] Source:PLoS One;11(12):e0164485, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Risk scores for patients who are at high risk for major bleeding complications during treatment with vitamin K antagonists (VKAs) do not perform that well. BLEEDS was initiated to search for new biomarkers that predict bleeding in these patients. OBJECTIVES: To describe the outline and objectives of BLEEDS and to examine whether the study population is generalizable to other VKA treated populations. METHODS: A cohort was created consisting of all patients starting VKA treatment at three Dutch anticoagulation clinics between January-2012 and July-2014. We stored leftover plasma and DNA following analysis of the INR. RESULTS: Of 16,706 eligible patients, 16,570 (99%) were included in BLEEDS and plasma was stored from 13,779 patients (83%). Patients had a mean age of 70 years (SD 14), 8713 were male (53%). The most common VKA indications were atrial fibrillation (10,876 patients, 66%) and venous thrombosis (3920 patients, 24%). 326 Major bleeds occurred during 17,613 years of follow-up (incidence rate 1.85/100 person years, 95%CI 1.66-2.06). The risk for major bleeding was highest in the initial three months of VKA treatment and increased when the international normalized ratio increased. These results and characteristics are in concordance with results from other VKA treated populations. CONCLUSION: BLEEDS is generalizable to other VKA treated populations and will permit innovative and unbiased research of biomarkers that may predict major bleeding during VKA treatment.
[Mh] Termos MeSH primário: Acenocumarol/efeitos adversos
Anticoagulantes/efeitos adversos
Fibrinolíticos/efeitos adversos
Hemorragia/diagnóstico
Femprocumona/efeitos adversos
[Mh] Termos MeSH secundário: Acenocumarol/administração & dosagem
Idoso
Idoso de 80 Anos ou mais
Anticoagulantes/administração & dosagem
Fibrilação Atrial/tratamento farmacológico
Fibrilação Atrial/fisiopatologia
Feminino
Fibrinolíticos/administração & dosagem
Seguimentos
Hemorragia/sangue
Hemorragia/induzido quimicamente
Seres Humanos
Coeficiente Internacional Normatizado
Estudos Longitudinais
Masculino
Meia-Idade
Femprocumona/administração & dosagem
Prognóstico
Fatores de Risco
Trombose Venosa/tratamento farmacológico
Trombose Venosa/fisiopatologia
Vitamina K/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Fibrinolytic Agents); 12001-79-5 (Vitamin K); I6WP63U32H (Acenocoumarol); Q08SIO485D (Phenprocoumon)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161210
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0164485


  7 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27795783
[Au] Autor:Dia K; Sarr SA; Mboup MC; Ba DM; Fall PD
[Ad] Endereço:Service Cardiologie Hôpital Principal de Dakar, Sénégal.
[Ti] Título:[Overdose in Vitamin K antagonists administration in Dakar: epidemiological, clinical and evolutionary aspects].
[Ti] Título:Les surdosages aux antivitamines K à Dakar: aspects épidémiologiques, cliniques et évolutifs..
[So] Source:Pan Afr Med J;24:186, 2016.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:fre
[Ab] Resumo:Vitamin K antagonists (VKA) are widely used for the prevention and curative treatment of thromboembolic events. This study aims to describe the epidemiological, clinical and evolutionary aspects of overdose in Vitamin K antagonists administration and determine its hemorrhagic factors. We conducted a monocentric cross-sectional descriptive study at the Principal Hospital in Dakar. All patients with an INR greater than 5 were included. We studied patients' gender and age, VKA used, drug use period, indications, INR value, associated drugs, presence of hemorrhage, immediate management and evolution. We enrolled 154 patients. Acenocoumarol was the most prescribed VKA. Sex ratio favoured women. The average age was 63 years. Overdose was asymptomatic in 43% of patients. Hemorrhagic symptoms were mainly represented by gingival bleeding, epistaxis. Major bleeding episodes were found in 8.6% of patients and they were represented by melena in 6 patients (3.9%), deep muscle hematoma in 2 patients (1.3%) and intracerebral parenchymal hematoma in 2 patients. Two patients had cardiovascular collapse associated with deglobulisation. Nonsteroidal anti-inflammatory drugs (NSAIDs) assumption was noted in 21% of patients. VKA assumption was suspended transiently in all patients. Mortality was 2%, due to intracranial hemorrhage. The reduction in VKA overdose requires caregivers to manage overdose factors and provide proper patient education.
[Mh] Termos MeSH primário: Anticoagulantes/envenenamento
Overdose de Drogas/epidemiologia
Vitamina K/antagonistas & inibidores
[Mh] Termos MeSH secundário: Acenocumarol/envenenamento
Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos Transversais
Overdose de Drogas/mortalidade
Feminino
Hematoma/induzido quimicamente
Hematoma/epidemiologia
Hemorragia/induzido quimicamente
Hemorragia/epidemiologia
Seres Humanos
Coeficiente Internacional Normatizado
Hemorragias Intracranianas/induzido quimicamente
Hemorragias Intracranianas/epidemiologia
Hemorragias Intracranianas/mortalidade
Masculino
Meia-Idade
Senegal/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 12001-79-5 (Vitamin K); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170224
[Lr] Data última revisão:
170224
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE


  8 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27762223
[Au] Autor:van Spil WE; Steenbergen E; Verhave JC
[Ad] Endereço:Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands.
[Ti] Título:A fatty cause of acute renal failure.
[So] Source:Neth J Med;74(8):365, 2016 Oct.
[Is] ISSN:1872-9061
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Acenocumarol/efeitos adversos
Lesão Renal Aguda/patologia
Anticoagulantes/efeitos adversos
Embolia de Colesterol/patologia
Embolia Pulmonar/tratamento farmacológico
[Mh] Termos MeSH secundário: Lesão Renal Aguda/induzido quimicamente
Lesão Renal Aguda/diagnóstico
Idoso
Aneurisma da Aorta Abdominal/complicações
Embolia de Colesterol/induzido quimicamente
Embolia de Colesterol/diagnóstico
Seres Humanos
Rim/patologia
Masculino
Embolia Pulmonar/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161021
[St] Status:MEDLINE


  9 / 1119 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27754317
[Au] Autor:Warzecha Z; Sendur P; Ceranowicz P; Dembinski M; Cieszkowski J; Kusnierz-Cabala B; Olszanecki R; Tomaszewska R; Ambrozy T; Dembinski A
[Ad] Endereço:Department of Physiology, Faculty of Medicine, Jagiellonian University Medical College, 16 Grzegórzecka St., 31-531 Cracow, Poland. mpwarzec@cyf-kr.edu.pl.
[Ti] Título:Protective Effect of Pretreatment with Acenocoumarol in Cerulein-Induced Acute Pancreatitis.
[So] Source:Int J Mol Sci;17(10), 2016 Oct 12.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Coagulation is recognized as a key player in inflammatory and autoimmune diseases. The aim of the current research was to examine the effect of pretreatment with acenocoumarol on the development of acute pancreatitis (AP) evoked by cerulein. METHODS: AP was induced in rats by cerulein administered intraperitoneally. Acenocoumarol (50, 100 or 150 µg/kg/dose/day) or saline were given once daily for seven days before AP induction. RESULTS: In rats with AP, pretreatment with acenocoumarol administered at the dose of 50 or 100 µg/kg/dose/day improved pancreatic histology, reducing the degree of edema and inflammatory infiltration, and vacuolization of acinar cells. Moreover, pretreatment with acenocoumarol given at the dose of 50 or 100 µg/kg/dose/day reduced the AP-evoked increase in pancreatic weight, serum activity of amylase and lipase, and serum concentration of pro-inflammatory interleukin-1ß, as well as ameliorated pancreatic DNA synthesis and pancreatic blood flow. In contrast, acenocoumarol given at the dose of 150 µg/kg/dose did not exhibit any protective effect against cerulein-induced pancreatitis. CONCLUSION: Low doses of acenocoumarol, given before induction of AP by cerulein, inhibit the development of that inflammation.
[Mh] Termos MeSH primário: Acenocumarol/farmacologia
Ceruletídeo
Pâncreas/efeitos dos fármacos
Pancreatite/induzido quimicamente
Pancreatite/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Anticoagulantes/farmacologia
Relação Dose-Resposta a Droga
Lipase/sangue
Masculino
Tamanho do Órgão/efeitos dos fármacos
Pâncreas/patologia
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 888Y08971B (Ceruletide); EC 3.1.1.3 (Lipase); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170512
[Lr] Data última revisão:
170512
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161019
[St] Status:MEDLINE


  10 / 1119 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27734812
[Au] Autor:Vannucchi A; Masi A; Vestrini G; Tonelli F
[Ti] Título:Extraperitoneal hemorrhagic rupture of a simple hepatic cyst. A case report and literature review.
[So] Source:Ann Ital Chir;87, 2016 Sep 30.
[Is] ISSN:2239-253X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Hemorrhagic rupture is a very rare complication of a simple hepatic cyst. We report the first case of a totally extraperitoneal rupture of a recurrent cyst, occurred in a 73-year-old man who presented with acute right hypochondralgia. Computed tomography revealed the rupture of a large hemorrhagic cyst in the right liver lobe and the formation of a voluminous hematoma in the retroperitoneal space. Despite the absence of hemoperitoneum, the entity of the bleeding led us to perform an urgent and successful surgical intervention. A review of the literature was conducted. To date, 9 cases of hemorrhagic rupture of simple hepatic cyst have been described and our case is the first one characterized by extraperitoneal bleeding. Our clinical management was in accordance with the majority of the other Authors. Different surgical procedures have been proposed and the best approach has not been established yet. However, the laparotomic approach should be preferred for a better control of the bleeding. In conclusion, the hemorrhagic rupture of a liver cyst is a life-threatening complication and a prompt surgery is necessary to prevent the hypovolemic shock. KEY WORDS: Extraperitoneal rupture, Hemorrhagic rupture, Simple hepatic cyst.
[Mh] Termos MeSH primário: Cistos/complicações
Hematoma/etiologia
Hepatopatias/complicações
[Mh] Termos MeSH secundário: Acenocumarol/efeitos adversos
Acenocumarol/uso terapêutico
Idoso
Anticoagulantes/efeitos adversos
Anticoagulantes/uso terapêutico
Cistos/diagnóstico por imagem
Cistos/cirurgia
Drenagem
Emergências
Transfusão de Eritrócitos
Hematoma/diagnóstico por imagem
Hematoma/cirurgia
Hematoma/terapia
Hemostasia Cirúrgica
Seres Humanos
Hepatopatias/diagnóstico por imagem
Hepatopatias/cirurgia
Masculino
Recidiva
Espaço Retroperitoneal
Ruptura Espontânea
Trombofilia/tratamento farmacológico
Tomografia Computadorizada por Raios X
Ultrassonografia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); I6WP63U32H (Acenocoumarol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161014
[St] Status:MEDLINE



página 1 de 112 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde